Could a common drug slow Alzheimer's? new study tests rapamycin
NCT ID NCT04629495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug rapamycin is safe and tolerable for older adults with mild memory problems or early Alzheimer's disease. About 40 participants will take rapamycin for 12 months while researchers monitor side effects and changes in memory and thinking. The goal is to see if this drug, already used for other conditions, might help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Could your brain help unlock Alzheimer's secrets?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a Voice-Based app map healthy brain aging across 80 years?